Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis
- 1 August 1989
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 98 (4) , 495-499
- https://doi.org/10.1007/bf00441948
Abstract
It has been shown that the hallucinogenic potencies of LSD, the phenylisopropylamines, such as DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) and DOI (4-iodo-2,5-dimethoxyphenylisopropylamine), and the indoleaklylamines, such as DMT (dimethyltryptamine) and 5-OMe-DMT (5-methoxy-dimethyltryptamine), strongly correlate with their in vitro 5-HT2 receptor binding affinities in rat cortical homogenates. In order to ascertain if this correlation applies to human 5-HT2 receptors as well, we examined the affinities of 13 psychoactive compounds at 3H-ketanserin-labelled 5-HT2 receptors in human cortical samples. Both radioligand binding and autoradiographical procedures were used. As in rat brain d-LSD was the most potent displacer of 3H-ketanserin specific binding with a K i of 0.9 nM. The phenylisopropylamine DOI also displayed high affinity (K i of 6 nM). Stereospecific interactions were found with DOB; (-_ DOB had a K i of 17 nM while (+) DOB had a K i of 55 nM. The behaviorally active compound DOM (4-methyl-2,5-phenylisopropylamine) had an affinity of 162 nM while its behaviorally less active congener iso-DOM had an affinity of 6299 nM. The indolealkylamines 5-OMe-DMT and DMT competed with moderate affinities (207 and 462 nM, respectively). In general, Hill coefficients were significantly less than unity which is consistent with an agonist interaction with 5-HT2 receptors. MDMA, a substituted amphetamine analog was inactive with a K i of greater than 10 μM. A strong correlation was found for the hallucinogen affinities and human hallucinogenic potencies (r=0.97). Also, human and rat brain 5-HT2 receptor affinities were strongly correlated (r=0.99). These results strongly support the hypothesis that the hallucinogenic effects of these drugs in humans are mediated in whole or in part via 5-HT2 receptors. Furthermore, these studies imply that treatment with 5-HT2 receptor antagonists may be effective in reversing the hallucinogenic effects caused by the ingestion, of LSD and LSD-like drugs.This publication has 16 references indexed in Scilit:
- [125I]SCH 23982, a ‘selective’ D-1 receptor antagonist, labels with high affinity 5-HT1C sites in pig choroid plexusEuropean Journal of Pharmacology, 1988
- Indolealkylamine analogs share 5-HT2 binding characteristics with phenylalkylamine hallucinogensEuropean Journal of Pharmacology, 1988
- Iodine-125 labeled 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane: an iodinated radioligand that specifically labels the agonist high-affinity state of 5-HT2 serotonin receptorsJournal of Medicinal Chemistry, 1988
- Non-serotonergic [3H]ketanserin binding sites in striatal membranes are associated with a dopac release system on dopaminergic nerve endingsEuropean Journal of Pharmacology, 1987
- Effect of hallucinogens on spontaneous and sensory-evoked locus coeruleus unit activity in the rat: reversal by selective 5-HT2antagonistsBrain Research, 1986
- 2-Pyrrolidinone and succinimide endogenously present in several mammalian speciesLife Sciences, 1984
- A practical computer-based approach to the analysis of radioligand binding experimentsComputer Programs in Biomedicine, 1983
- Antagonism of the effects of the hallucinogen dom and the purported 5-HT agonist quipazine by 5-HT2 antagonistsEuropean Journal of Pharmacology, 1983
- Drug‐induced discrimination: A description of the paradigm and a review of its specific application to the study of hallucinogenic agentsMedicinal Research Reviews, 1983
- Properties of [3H]Prazosin‐Labeled α1Adrenergic Receptors in Rat Brain and Porcine Neurointermediate Lobe TissueJournal of Neurochemistry, 1983